Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$143.31 USD

143.31
476,795

-0.40 (-0.28%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $143.37 +0.06 (0.04%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Alnylam (ALNY) Down 16.8% Since Last Earnings Report?

by Zacks Equity Research

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioMarin Announces Data on Hemophilia Candidate, Shares Fall

by Zacks Equity Research

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Regeneron (REGN) Stock Down on Earnings, Sales Miss in Q1

by Zacks Equity Research

Regeneron's (REGN) first-quarter performance was dismal with the company missing on both earnings and sales estimates.

Regeneron (REGN) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter results.

Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of 22.83% and 51.68%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

by Zacks Equity Research

The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

by Zacks Equity Research

Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

by Zacks Equity Research

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Ekta Bagri headshot

4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

by Ekta Bagri

We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

by Zacks Equity Research

Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

by Zacks Equity Research

Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Alnylam's (ALNY) Impressive Pipeline Drives Share Price

by Zacks Equity Research

Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

Alnylam Files Application for Hypertension Candidate in UK

by Zacks Equity Research

Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.

Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report?

by Zacks Equity Research

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam Stock Down Despite Positive Phase III Givosiran Data

by Zacks Equity Research

Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.

Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus

by Zacks Equity Research

The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.

Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.

Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of 7.61% and 67.92%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio

5 Best Biotech Bets Likely to Outperform Estimates in Q4

by Zacks Equity Research

Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs

by Zacks Equity Research

A low key week for the biotech sector with regular drug approvals and pipeline updates.